4 news items
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
MBRX
18 Apr 24
toxicity profile than traditional intensive therapy
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
MBRX
10 Apr 24
confirmed no toxicity to the heart/myocardium.These data are clearly aligned with the lack of drug-related
Moleculin Biotech Provided A Preliminary Update On Recent Clinical Activity And Expected Near Term Milestones For Its Lead Program MB-106 For The Treatment Of Acute Myeloid Leukemia
MBRX
25 Mar 24
therapies
All 82 Annamycin subjects (in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
MBRX
25 Mar 24
(in multiple studies) continue to show no signs of cardiotoxicity during study; Lower toxicity profile than traditional intensive therapy
- Prev
- 1
- Next